DGAP-Adhoc: Mubadala Investment Company and Novo Holdings A/S invest € 250 million in Evotec SE
|
DGAP-Ad-hoc: Evotec SE / Key word(s): Capital Increase Disclosure of an inside information according to Article 17 MAR In this private capital increase, Mubadala Investment Company will invest € 200 million to subscribe 9,182,652 Evotec shares at a share price of € 21.7802 per share representing approx. 5.6% of outstanding shares. Evotec gains with Mubadala Investment Company a new long-term strategic oriented shareholder with extensive experience and expertise in the biotech industry. Evotec's existing long-term shareholder Novo Holdings A/S will invest € 50 million to subscribe 2,295,663 shares of Evotec at a same share price to reinforce its ownership at approx. 11.0%, to secure financial flexibility for the Company. The placement was made at 2.5% discount to the five-day volume weighted average price ("VWAP") of € 22.3387 prior to the Xetra closing auction on 12th October 2020. After the registration of the capital increase in the commercial register, the share capital of the Company will increase to € 163,375,808 or 163,375,808 ordinary bearer shares. While maintaining the business outlook 2020 unchanged, Evotec will be using the proceeds from the capital increase to pursue its unique strategy to become the global leading platform company for the modality-agnostic development of innovative first-in-class and best-in-class therapeutic approaches resulting in a very large co-owned pipeline.
Information and Explanation of the Issuer to this News: Contact: Dr Werner Lanthaler, Chief Executive Officer Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany Phone: +49.(0)40.560 81-242 Email: [email protected]
13-Oct-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Evotec SE |
| Manfred Eigen Campus / Essener Bogen 7 | |
| 22419 Hamburg | |
| Germany | |
| Phone: | +49 (0)40 560 81-0 |
| Fax: | +49 (0)40 560 81-222 |
| E-mail: | [email protected] |
| Internet: | www.evotec.com |
| ISIN: | DE0005664809 |
| WKN: | 566480 |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1140411 |
| End of Announcement | DGAP News Service |
|
|
1140411 13-Oct-2020 CET/CEST
Evotec SE Stock
Currently there is a rather positive sentiment for Evotec SE with 4 Buy predictions and 1 Sell predictions.
With a target price of 21 € there is potential for a 119.67% increase which would mean more than doubling the current price of 9.56 € for Evotec SE.
